Costs of Common Psoriasis Medications, 2010-2014
March 2016 | Volume 15 | Issue 3 | Original Article | 305 | Copyright © 2016
Sara M. James BS,a Dane E. Hill MD,a and Steven R. Feldman MD PhDa,b,c
aCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC
bDepartment of Pathology, Wake Forest School of Medicine, Winston-Salem, NC
cDepartment of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC
BACKGROUND: Costs for psoriasis have increased in recent years, in part due to the introduction of biologic agents.
OBJECTIVE: To identify the most common and most costly (from the payer perspective) drugs used in the treatment of psoriasis.
METHODS: We analyzed patient data from a large claims-based database in order to identify the most common and most costly medications used in the treatment of psoriasis from 2010 to 2014.
RESULTS: The three most common psoriasis medications, accounting for 81.1% of all psoriasis medications, were topical corticosteroids. The three most costly drugs, accounting for only 9.6% of all psoriasis medications, were biologics, accounting for 86% of the cost of psoriasis medications.
CONCLUSIONS: Biologic agents are used far less commonly in the treatment of psoriasis than topical treatments. Despite the relatively small number of patients using biologic agents, biologics are responsible for a large proportion of the cost of psoriasis pharmacotherapy.
J Drugs Dermatol. 2016;15(3):305-308.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Psoriasis is a chronic inflammatory disease that affects an estimated 3% of the population in the United States.1 Psoriasis creates a large economic burden for patients and payers; estimates of the direct costs of psoriasis range from $51.7 billion to $63.2 billion with an additional $23.9 billion to $35.4 billion from indirect costs.2 Within an environment of ever-growing healthcare costs, the medical cost of psoriasis has increased in recent years, which is in part explained by the introduction of biologic agents.3, 4
Most people with psoriasis have mild disease that can be managed with topical medications.5 Biologic agents are typically reserved for moderate-to-severe psoriasis.6 To better manage psoriasis treatment costs, it is essential to know which medications are driving the cost of psoriasis management. The purpose of this study is to determine the most commonly prescribed and most costly drugs used in the treatment of psoriasis, and to test the hypothesis that biologic agents are responsible for a large portion of the medical cost of psoriasis.
Data were collected using the Humana database, a large claims-based database encompassing 18,162,539 patient records. We searched by ICD-9 code for psoriasis (696.1) and identified psoriasis patients ≤64 years of age who had seen a dermatologist at least once between 2010 and 2014. Patients age 65 and over were excluded because they are likely to have Medicare. From a database of all medications prescribed for psoriasis patients from 2010-2014, we compiled lists of the 100 drugs most commonly used and the 100 drugs with the highest total cost. We narrowed the list to include drugs whose primary indication is treatment of psoriasis. Generic and brand name drugs with the same formulations were combined. Percentage of total cost was calculated using the total cost of all psoriasis medications on the list of 100 most costly drugs.
25,986 psoriasis patients in the database were prescribed medications between 2010 and 2014. The drug categories used by psoriasis patients accounting for the most common drugs were antimicrobials, psoriasis treatments, psychiatric drugs, and analgesics (Table I). We identified 18 medications with a primary indication for psoriasis treatment; there were 16 drugs after combining generic and brand name formulations (Table II). Biologic agents were used by 9.6% of psoriasis patients; two biologic drugs (adalimumab and etanercept) appeared on the list of common medications. The five most commonly used drugs were topical corticosteroids and vitamin D analogues. Topical treatments were prescribed much more frequently than any other treatment modality (Figure 1).
The drug categories used by psoriasis patients accounting for the most cost were for psoriasis, diabetes, and psychiatric disorders. Of these most costly medications, we identified 27 drugs with a primary indication for psoriasis treatment; there were 18 drugs after combining generic and brand name formulations (Table IV). The three most costly drugs were biologic agents, which altogether made up 86% of the total cost (Figure 2).